Skip to content
Subscriber Only

Cancer Doctors Plan to Compare Value of Expensive Drugs

The world’s largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.

The American Society of Clinical Oncology is weighing efficacy, side effects and price using an algorithm to determine the relative value of drugs, focusing first on therapies for advanced cases of lung and prostate cancer and for multiple myeloma, said Richard Schilsky, the group’s chief medical officer. The task force developing the system plans to present it for public comment later this year, he said.